About Kailera
Kailera is a company based in Waltham (United States) founded in 2024 by Ron Renaud.. Kailera has raised $1 billion across 2 funding rounds from investors including Royalty Pharma, Citadel and Janus Henderson Investors. The company has 4 employees as of April 04, 2024. Kailera offers products and services including KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729. Kailera operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Adocia, Rezolute and Carmot, among others.
- Headquarter Waltham, United States
- Employees 4 as on 04 Apr, 2024
- Founders Ron Renaud
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$705.98 K (USD)11.43as on Mar 31, 2022
-
Net Profit
$29.86 K (USD)154.53as on Mar 31, 2022
-
EBITDA
$66.13 K (USD)340.13as on Mar 31, 2022
-
Total Equity Funding
$1 B (USD)
in 2 rounds
-
Latest Funding Round
$600 M (USD), Series B
Oct 14, 2025
-
Investors
Royalty Pharma
& 13 more
-
Employee Count
4
as on Apr 04, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kailera
Kailera offers a comprehensive portfolio of products and services, including KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Dual agonist for treating obesity and type 2 diabetes effectively.
Small molecule agonist targeting obesity and diabetes management.
Daily tablet for obesity and diabetes treatment development.
Tri-agonist peptide for obesity and related conditions.
Funding Insights of Kailera
Kailera has successfully raised a total of $1B across 2 strategic funding rounds. The most recent funding activity was a Series B round of $600 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $600.0M
-
First Round
First Round
(01 Oct 2024)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series B - Kailera | Valuation | Bain Capital Private Equity | |
| Oct, 2024 | Amount | Series A - Kailera | Valuation | Atlas Venture , Bain Capital Life Sciences |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kailera
Kailera has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Royalty Pharma, Citadel and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Founded Year | Domain | Location | |
|
Life Sciences focused VC firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kailera
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kailera
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kailera Comparisons
Competitors of Kailera
Kailera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Adocia, Rezolute and Carmot, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| domain | founded_year | HQ Location |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kailera
Frequently Asked Questions about Kailera
When was Kailera founded?
Kailera was founded in 2024.
Where is Kailera located?
Kailera is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Who is the current CEO of Kailera?
Ron Renaud is the current CEO of Kailera. They have also founded this company.
Is Kailera a funded company?
Kailera is a funded company, having raised a total of $1B across 2 funding rounds to date. The company's 1st funding round was a Series A of $400M, raised on Oct 01, 2024.
How many employees does Kailera have?
As of Apr 04, 2024, the latest employee count at Kailera is 4.
What is the annual revenue of Kailera?
Annual revenue of Kailera is $705.98K as on Mar 31, 2022.
What does Kailera do?
Kailera was founded in 2024 and is based in Waltham, United States. Focus is placed on the biotechnology sector, where therapies for obesity and type 2 diabetes are developed. A pipeline of candidates is maintained, including KAI-9531 as an injectable GLP-1GIP receptor dual agonist and KAI-7535 as an oral small molecule. Operations center on advancing these treatments for metabolic conditions.
Who are the top competitors of Kailera?
Kailera's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
What products or services does Kailera offer?
Kailera offers KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729.
Who are Kailera's investors?
Kailera has 14 investors. Key investors include Royalty Pharma, Citadel, Janus Henderson Investors, CPP Investments, and RTW Investments.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.